Aclarubicin, azacitidine and venetoclax for acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of three drugs—aclarubicin, azacitidine, and venetoclax—for people with acute myeloid leukemia (AML) who cannot have intensive chemotherapy, or whose leukemia has returned after treatment. The goal is to see if this combination helps control the leukemia with manageable side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have acute myeloid leukemia (AML) that is either newly diagnosed and you are not able to get intensive chemo, or that came back after prior intensive chemo
- Be generally able to care for yourself (ECOG score under 3)
- Have a white blood cell count below 25 – but hydroxyurea can be used to bring it down
- Have adequate liver and kidney function
- Be able to swallow capsules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
This Phase 1 trial tests a combination of azacitidine, venetoclax, and donor NK cells to treat acute myeloid leukemia (AML) or certain AML-like syndromes. It’s designed mainly to find safe dosing and whether this approach can control the leukemia.
This trial tests a combination of three oral medications (chidamide, venetoclax, and azacitidine) for people newly diagnosed with acute myeloid leukemia (AML) who cannot receive strong chemotherapy. The goal is to see if this gentler treatment can work well with fewer side effects.
This Phase 2 study tests whether the combination of azacitidine and venetoclax can help people with acute myeloid leukemia (AML) who can’t handle standard intensive chemotherapy, including some relapsed or refractory cases. It also involves extra optional-style lab testing on your leukemia (bio-banking and “-omics” profiling) to learn which drug sensitivities may matter.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.